Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance - PubMed (original) (raw)

Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance

Klaus Leth Mortensen et al. J Clin Microbiol. 2011 Jun.

Abstract

Respiratory tract colonization by molds in patients with cystic fibrosis (CF) were analyzed, with particular focus on the frequency, genotype, and underlying mechanism of azole resistance among Aspergillus fumigatus isolates. Clinical and demographic data were also analyzed. A total of 3,336 respiratory samples from 287 CF patients were collected during two 6-month periods in 2007 and 2009. Azole resistance was detected using an itraconazole screening agar (4 mg/liter) and the EUCAST method. cyp51A gene sequencing and microsatellite genotyping were performed for isolates from patients harboring azole-resistant A. fumigatus. Aspergillus spp. were present in 145 patients (51%), of whom 63 (22%) were persistently colonized. Twelve patients (4%) harbored other molds. Persistently colonized patients were older, provided more samples, and more often had a chronic bacterial infection. Six of 133 patients (4.5%) harbored azole-nonsusceptible or -resistant A. fumigatus isolates, and five of those six patients had isolates with Cyp51A alterations (M220K, tandem repeat [TR]/L98H, TR/L98H-S297T-F495I, M220I-V101F, and Y431C). All six patients were previously exposed to azoles. Genotyping revealed (i) microevolution for A. fumigatus isolates received consecutively over the 2-year period, (ii) susceptible and resistant isolates (not involving TR/L98H isolates) with identical or very closely related genotypes (two patients), and (iii) two related susceptible isolates and a third unrelated resistant isolate with a unique genotype and the TR/L98H resistance combination (one patient). Aspergilli were frequently found in Danish CF patients, with 4.5% of the A. fumigatus isolates being azole nonsusceptible or resistant. Genotyping suggested selection of resistance in the patient as well as resistance being achieved in the environment.

PubMed Disclaimer

Figures

Fig. 1.

Phylogenetic tree of A. fumigatus isolates from Danish CF patients with azole-resistant or -nonsusceptible isolates (R1 to R3), with both azole-resistant and -susceptible isolates (R4 to R6), and with a susceptible isolate(s) (S1 and S2) in relation to azole-resistant environmental isolates from Denmark (T11, T18, T22, and R13) and to isolates from patients from a geographically separated environment in Manchester, United Kingdom (F, A, and AF). _S, _nS, and _R indicate azole-susceptible, -nonsusceptible, and -resistant isolates, respectively; * indicates TR/L98H isolates. The scale bar indicates the number of nucleotide substitutions per site.

Cited by

Analysis of promoter function in Aspergillus fumigatus.
Paul S, Klutts JS, Moye-Rowley WS. Paul S, et al. Eukaryot Cell. 2012 Sep;11(9):1167-77. doi: 10.1128/EC.00174-12. Epub 2012 Jul 27. Eukaryot Cell. 2012. PMID: 22843562 Free PMC article.
Comparative Genomics of Serial Isolates of Cryptococcus neoformans Reveals Gene Associated With Carbon Utilization and Virulence.
Ormerod KL, Morrow CA, Chow EW, Lee IR, Arras SD, Schirra HJ, Cox GM, Fries BC, Fraser JA. Ormerod KL, et al. G3 (Bethesda). 2013 Apr 9;3(4):675-686. doi: 10.1534/g3.113.005660. G3 (Bethesda). 2013. PMID: 23550133 Free PMC article.
Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism.
Camps SM, Rijs AJ, Klaassen CH, Meis JF, O'Gorman CM, Dyer PS, Melchers WJ, Verweij PE. Camps SM, et al. J Clin Microbiol. 2012 Aug;50(8):2674-80. doi: 10.1128/JCM.00335-12. Epub 2012 Jun 6. J Clin Microbiol. 2012. PMID: 22675126 Free PMC article.
Are Cystic Fibrosis Aspergillus fumigatus Isolates Different? Intermicrobial Interactions with Pseudomonas.
Nazik H, Moss RB, Karna V, Clemons KV, Banaei N, Cohen K, Choudhary V, Stevens DA. Nazik H, et al. Mycopathologia. 2017 Apr;182(3-4):315-318. doi: 10.1007/s11046-016-0087-3. Epub 2016 Nov 7. Mycopathologia. 2017. PMID: 27822731
Short-term evolution strategies for host adaptation and drug escape in human fungal pathogens.
Beekman CN, Ene IV. Beekman CN, et al. PLoS Pathog. 2020 May 14;16(5):e1008519. doi: 10.1371/journal.ppat.1008519. eCollection 2020 May. PLoS Pathog. 2020. PMID: 32407384 Free PMC article. Review. No abstract available.

References

1. Alcazar-Fuoli L., Mellado E., Alastruey-Izquierdo A., Cuenca-Estrella M., Rodriguez-Tudela J. L. 2008. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob. Agents Chemother. 52:1244–1251 - PMC - PubMed
1. Amin R., Dupuis A., Aaron S. D., Ratjen F. 2010. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 137:171–176 - PubMed
1. Amorim A., Guedes-Vaz L., Araujo R. 2010. Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy. Int. J. Antimicrob. Agents 35:396–399 - PubMed
1. Bakare N., Rickerts V., Bargon J., Just-Nubling G. 2003. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 46:19–23 - PubMed
1. Balajee S. A., Gribskov J. L., Hanley E., Nickle D., Marr K. A. 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4:625–632 - PMC - PubMed

Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance - PubMed (original) (raw)